Altimmune Inc (ALT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Altimmune Inc (ALT) has a cash flow conversion efficiency ratio of -0.086x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.45 Million) by net assets ($224.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Altimmune Inc stock valuation for the company's overall valuation and market capitalisation.
Altimmune Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Altimmune Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Altimmune Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Altimmune Inc ranked by their cash flow conversion efficiency. Explore Altimmune Inc (ALT) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PEPPER MONEY LTD.
F:X95
|
N/A |
|
Promotora de Informaciones SA
MC:PRS
|
-0.242x |
|
Zhengzhou Qianweiyangchu Food Co Ltd
SHE:001215
|
0.044x |
|
Long Chen Paper Co Ltd
TW:1909
|
0.044x |
|
CellaVision AB
ST:CEVI
|
0.058x |
|
SHELF DRILLING LTD
F:6SD
|
N/A |
|
Coca-Cola Europacific Partners PLC
LSE:CCEP
|
0.105x |
|
HaiXin Foods Co Ltd
SHE:002702
|
0.122x |
Annual Cash Flow Conversion Efficiency for Altimmune Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Altimmune Inc from 2005 to 2025. View today's stock price for Altimmune Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $224.89 Million | $-67.53 Million | -0.300x | +53.55% |
| 2024-12-31 | $123.51 Million | $-79.85 Million | -0.647x | -65.53% |
| 2023-12-31 | $194.10 Million | $-75.81 Million | -0.391x | -15.63% |
| 2022-12-31 | $185.29 Million | $-62.59 Million | -0.338x | +14.03% |
| 2021-12-31 | $199.13 Million | $-78.24 Million | -0.393x | -157.70% |
| 2020-12-31 | $225.88 Million | $-34.44 Million | -0.152x | +27.72% |
| 2019-12-31 | $45.52 Million | $-9.60 Million | -0.211x | -8.54% |
| 2018-12-31 | $48.31 Million | $-9.39 Million | -0.194x | +53.20% |
| 2017-12-31 | $48.68 Million | $-20.21 Million | -0.415x | -104.01% |
| 2016-12-31 | $19.46 Million | $201.51 Million | 10.355x | +5461.03% |
| 2015-12-31 | $16.65 Million | $-3.22 Million | -0.193x | +58.34% |
| 2014-12-31 | $18.27 Million | $-8.47 Million | -0.464x | +52.54% |
| 2013-12-31 | $7.34 Million | $-7.17 Million | -0.977x | -391.08% |
| 2012-12-31 | $11.67 Million | $-2.32 Million | -0.199x | +59.61% |
| 2011-12-31 | $15.85 Million | $-7.81 Million | -0.493x | +59.53% |
| 2010-12-31 | $12.21 Million | $-14.86 Million | -1.217x | +91.85% |
| 2009-12-31 | $1.88 Million | $-28.15 Million | -14.936x | -2046.03% |
| 2008-12-31 | $18.96 Million | $-13.20 Million | -0.696x | -107.07% |
| 2007-12-31 | $40.57 Million | $-13.64 Million | -0.336x | -1355.97% |
| 2006-12-31 | $57.11 Million | $1.53 Million | 0.027x | +236.37% |
| 2005-12-31 | $69.68 Million | $554.33K | 0.008x | -- |
About Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.